Clinical trials: Zoledronic acid, completed
Breast Cancer, Osteoporosis
Zoledronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy After Surgery For Early Stage Breast Cancer
RATIONALE: It is not yet known whether zoledronate is effective in preventing bone loss in premenopausal women who are receiving adjuvant chemotherapy after undergoing surgery for early stage breast cancer.
- Trial name
- NCT00049452
- Testing
- zoledronic acid
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer
Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates
The purpose of this trial is to determine the effectiveness of AMG 162 in reducing urinary N-telopeptide in advanced cancer subjects with bone metastases.
- Conditions
- Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer, Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma
- Trial name
- NCT00104650
- Testing
- AMG 162 180 mg (SC) q 12 weeks, IV Bisphosphonate q 4 weeks, AMG 162- 180 mg q 4 weeks
- Volunteers
- 111 people
- Sponsor
- Amgen
Prostate Cancer
Calcitriol and Zoledronate in Treating Patients With Progressive Prostate Cancer
RATIONALE: Calcitriol may help prostate cancer cells develop into normal cells. Zoledronate may delay or prevent the formation of bone metastases.
- Trial name
- NCT00004928
- Testing
- calcitriol, zoledronic acid
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer
Effectiveness of Zoledronic Acid in the Prevention of Osteoporosis in Early Breast Cancer Patients Receiving Letrozole
The purpose of this study is to determine whether zoledronic acid given intravenously every 6 months can prevent reduction in bone mineral density in women with early stage breast cancer receiving adjuvant therapy with the…
- Trial name
- NCT00376740
- Testing
- zoledronic acid
- Where
- 2 sites in Israel
- Volunteers
- 90 people
- Sponsor
- Soroka University Medical Center
First or Second Line HER2-negative Breast Cancer, Metastatic Disease Without Bone Metastasis
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
This study will evaluate zoledronic acid's anti-cancer effects and Circulating Tumor Cell (CTCs) measurements in patients with HER2-negative metastatic breast cancer without bone metastasis.
- Trial name
- MACS1295 (NCT01129336)
- Testing
- Zoledronic acid, Standard Therapy
- Where
- 33 sites in United States
- Volunteers
- 44 people
- Sponsor
- Novartis Pharmaceuticals
Spinal Cord Injury
Zoledronic Acid in Acute Spinal Cord Injury
Maintenance of bone mass following spinal cord injury (SCI) is essential to fracture prevention and the associated morbidity of bed rest and further secondary complications.
- Trial name
- NCT01642901
- Testing
- Zoledronic acid, normal saline 0.9%
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Thomas Jefferson University
Osteoporosis, Knee Osteoarthristis
The Effect of Long-term Use of Bisphosphonates on Femur Morphology
Recent studies have shown that bone modeling can occur throughout life, suggesting bone has a persistent ability of adapting structure to loading.
- Trial name
- NCT06621069
- Testing
- Bisphosphonates, Control
- Where
- China
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hutchinson-Gilford Progeria Syndrome
Treatment of the Hutchinson-Gilford Progeria Syndrome With a Combination of Pravastatin and Zoledronic Acid
We suggest treating the Hutchinson-Gilford Progeria Syndrome by two molecules (zoledronic acid and pravastatin).The therapeutic approach which we propose has for objectives to reduce, to prevent or to delay the gravest…
- Trial name
- NCT00731016
- Testing
- Zoledronic acid, pravastatin
- Where
- France
- Volunteers
- 15 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Breast Cancer, Metastatic Bone Disease
A Study to Examine the Effects of an Experimental Drug on Women With Breast Cancer and Metastatic Bone Disease (MBD)(0822-016)(COMPLETED)
This is a 4-week study to examine the effects of a new experimental medication on women with breast cancer and established bone metastases. This study will enroll approximately 45 women.
- Trial name
- NCT00399802
- Testing
- ZA, Odanacatib
- Volunteers
- 43 people
- Sponsor
- Merck Sharp & Dohme LLC
Osteoporosis
Replication of the HORIZON Pivotal Fracture Trial in Healthcare Claims Data
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials.
- Trial name
- NCT04736693
- Testing
- Raloxifene, Zoledronic Acid
- Where
- United States
- Volunteers
- 18,028 people
- Sponsor
- Brigham and Women's Hospital
Trochanteric Fracture of Femur, Osteoporotic Fracture of Femur
FARE Augmentation of Proximal Femoral Fractures With CaS/HA and Systemic ZA
The goal of this clinical trial is to investigate the new bone formation around a metal device in the femoral head in patients with osteoporotic hip fractures undergoing surgical treatment with nails.
- Conditions
- Trochanteric Fracture of Femur, Osteoporotic Fracture of Femur, Hip Fractures, Bone Density, Low
- Trial name
- NCT06135298
- Testing
- OSTEOSYNTHESIS, Zoledronic acid, CERAMENT BONE VOID FILLER (BVF)
- Where
- Turkey (Türkiye)
- Volunteers
- 20 people
- Sponsor
- Aksaray University
Osteoporosis
Study of AK156 in Primary Osteoporosis Patients
The purpose of this study is to investigate the efficacy and safety of AK156 in Japanese patients with primary osteoporosis.
- Trial name
- NCT01522521
- Testing
- AK156
- Where
- 20 sites in Japan
- Volunteers
- 600 people
- Sponsor
- Asahi Kasei Therapeutics Corporation
Solid Tumor, Osteosarcoma
Metronomic Chemotherapy in Patients With Advanced Solid Tumor With Bone Metastasis and Advanced Pretreated Osteosarcoma
This is a prospective open-labeled phase I trial based on a dose escalating study design assessing two dose levels of sirolimus when prescribed in combination with metronomic cyclophosphamide (CP), methotrexate (MT) and…
- Trial name
- METZOLIMOS (NCT02517918)
- Testing
- Sirolimus combined with CP, MT and ZA
- Where
- 3 sites in France
- Volunteers
- 23 people
- Sponsor
- Institut Bergonié
Prostate Cancer
Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
The purpose of this trial with Zometa is to investigate the effect ZOMETA 4 mg (zoledronic acid for injection in 100mg solution ) has in preventing associated bone loss in prostate cancer patients with bone metastasis when…
- Trial name
- NCT00035997
- Testing
- Zometa
- Where
- 56 sites in United States
- Volunteers
- 261 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Cancer, Prostate Cancer
Docetaxel and Prednisolone With or Without Zoledronic Acid and/or Strontium Chloride Sr 89 in Treating Patients With Prostate Cancer Metastatic to Bone That Has Not Responded to Hormone Therapy
RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisolone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00554918
- Testing
- docetaxel, prednisolone, zoledronic acid
- Where
- 16 sites in United Kingdom
- Volunteers
- 300 people
- Sponsor
- University Hospital Birmingham
Osseous Lesions From Metastatic Breast Cancer
Investigation of Changes in Bone Scan Imaging Before and After Intravenous Bisphosphonate Therapy for Osseous Metastases From Breast Cancer
The purpose of this study is to examine for changes in the bone scan after treating with zoledronic acid (Zometa™). This study is designed to show if intravenous (IV) bisphosphonates, which are infused by vein, such as…
- Trial name
- NCT00582920
- Testing
- Zometa™
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Paget's Disease of Bone
Efficacy and Safety of Single Dose of 5 mg Zoledronic Acid in Chinese Patients With Paget's Disease of Bone (PDB)
The purpose of this study is to document the efficacy and safety profiles of single intravenous dose of 5 mg zoledronic acid for the Chinese patients of Paget's Disease of Bone (PDB).
- Trial name
- NCT00774020
- Testing
- Zoledronic acid
- Where
- 4 sites in China
- Volunteers
- 9 people
- Sponsor
- Novartis Pharmaceuticals
Avascular Necrosis of Femoral Head
Efficacy of Zoledronic Acid in Preventing Collapse of the Osteonecrotic Femoral Head
The purpose of this study is to test the effect of zoledronic acid over 2 years in preventing early collapse and progression of joint dome depression (≥ 2 mm by X-ray) of the femoral head in patients with large (> 30%: criteria…
- Trial name
- EZAPCOFH (NCT00939900)
- Testing
- zoledronic acid (aclasta)
- Where
- South Korea
- Volunteers
- 110 people
- Sponsor
- Seoul National University Bundang Hospital
IOP, Osteoporosis
Bisphosphonates for Prevention of Post-Denosumab Bone Loss
The primary goal of the study is to assess the extent to which bisphosphonate therapy will prevent decreases in bone mass that may occur after cessation of denosumab in premenopausal women with idiopathic osteoporosis (IOP)…
- Trial name
- NCT03396315
- Testing
- Alendronate, Zoledronic Acid
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Columbia University
Breast Cancer, Bone Metastases
Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis
The goal of this clinical research study is to find the highest tolerable dose of dasatinib and Zometa (zoledronic acid) that can be given in combination for the treatment of breast cancer that has spread to the bone.
- Trial name
- NCT00566618
- Testing
- Dasatinib, Zoledronic Acid
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center